Skip to content

Study · Randomized controlled trial · n = 57 · 2004

3 results

Combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma.

Shuqun C, Mengchao W, Han C, Feng S, Jiahe Y, Wenming C, Peiun W, Yuxiang Z

Hepato-gastroenterology1 Sept 2004Cited by 14 (Europe PMC)

PMID15362772 (opens in a new tab)PepBankPUB-15362772
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with hepatocellular carcinoma after hepatectomy, thymosin alpha‑1 plus TACE did not change the one-year recurrence rate compared with TACE alone or hepatectomy only (83.3%, 87.0% and 87.5%, p=0.926).

    In plain wordsIn patients with liver cancer after surgery, adding thymosin alpha‑1 to TACE did not change one-year recurrence compared with TACE alone or surgery only.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeOne-year recurrence rate
    Study

    n = 57

    Comparator
    TACE alone (group B); hepatectomy only (group C)
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    One-year recurrence rate
    83.3%
    group A, thymosin alpha-1 plus TACE
    One-year recurrence rate
    87%
    group B, TACE
    One-year recurrence rate
    87.5%
    group C, hepatectomy only

    Source sentences

    Summary
    For group A, B and C, one-year recurrent rates were 83.3%, 87.0% and 87.5% (p=0.926), respectively.
    1 context sentence
    Summary · context
    From January 2000 to December 2002, 57 patients with hepatocellular carcinoma were randomly divided into three groups: Group A (n=18) received hepatectomy plus TACE and thymosin alpha1 postoperatively, group B (n=23) received hepatectomy plus TACE postoperatively and group C (n=16) received hepatectomy only.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with hepatocellular carcinoma after hepatectomy, time to recurrence was 7.0 months with thymosin alpha‑1 plus TACE, 5.0 months with TACE alone and 4.0 months with hepatectomy only (p=0.039).

    In plain wordsIn patients with liver cancer after surgery, cancer came back later with thymosin alpha‑1 plus TACE than with TACE alone or surgery only.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTime to recurrence
    Study

    n = 57

    Comparator
    TACE alone (group B); hepatectomy only (group C)
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Recurrent time
    7 months
    group A, thymosin alpha-1 plus TACE
    Recurrent time
    5 months
    group B, TACE
    Recurrent time
    4 months
    group C, hepatectomy only

    Source sentences

    Summary
    The recurrent time were 7.0, 5.0 and 4.0 months (p=0.039
    1 context sentence
    Summary · context
    From January 2000 to December 2002, 57 patients with hepatocellular carcinoma were randomly divided into three groups: Group A (n=18) received hepatectomy plus TACE and thymosin alpha1 postoperatively, group B (n=23) received hepatectomy plus TACE postoperatively and group C (n=16) received hepatectomy only.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with hepatocellular carcinoma after hepatectomy, median survival was 10.0 months with thymosin alpha‑1 plus TACE, 7.0 months with TACE alone and 8.0 months with hepatectomy only (p=0.002).

    In plain wordsIn patients with liver cancer after surgery, median survival was longer with thymosin alpha‑1 plus TACE than with TACE alone or surgery only.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMedian survival
    Study

    n = 57

    Comparator
    TACE alone (group B); hepatectomy only (group C)
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Measurements

    Median survival
    10 months
    group A, thymosin alpha-1 plus TACE
    Median survival
    7 months
    group B, TACE
    Median survival
    8 months
    group C, hepatectomy only

    Source sentences

    Summary
    the median survival were 10.0, 7.0 and 8.0 months (p=0.002), respectively.
    1 context sentence
    Summary · context
    From January 2000 to December 2002, 57 patients with hepatocellular carcinoma were randomly divided into three groups: Group A (n=18) received hepatectomy plus TACE and thymosin alpha1 postoperatively, group B (n=23) received hepatectomy plus TACE postoperatively and group C (n=16) received hepatectomy only.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.